MRNA Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MRNA from our risk checks.
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.28 |
| 52 Week High | US$170.47 |
| 52 Week Low | US$62.55 |
| Beta | 1.67 |
| 11 Month Change | -16.98% |
| 3 Month Change | -51.24% |
| 1 Year Change | -40.41% |
| 33 Year Change | -84.12% |
| 5 Year Change | 277.86% |
| Change since IPO | 267.10% |
Recent News & Updates
Recent updates
Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling
Sep 12Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Aug 26Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop
Aug 18
Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results
Aug 03Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
Jul 30Moderna: Really Strong Competition
Jun 30Moment Of Truth Approaches For Moderna's RSV Vaccine
Jun 18What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You
Jun 06Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
May 23Moderna Q1: A Promising Pipeline Is Undervalued
May 15We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed
Apr 30Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares
Apr 22Moderna: Considering The Cancer Vaccine Angle
Apr 11Moderna Continues To Build A Pipeline
Apr 03Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 27Moderna: Counting On Pipeline Too Much
Feb 23Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World
Feb 16Moderna: Fade 2025 Outlook
Jan 15Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 29Shareholder Returns
| MRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | 2.3% | 1.6% |
| 1Y | -40.4% | 15.9% | 22.0% |
Return vs Industry: MRNA underperformed the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: MRNA underperformed the US Market which returned 22% over the past year.
Price Volatility
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRNA's share price has been volatile over the past 3 months.
Volatility Over Time: MRNA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| MRNA fundamental statistics | |
|---|---|
| Market cap | US$26.78b |
| Earnings (TTM) | -US$5.87b |
| Revenue (TTM) | US$5.05b |
5.2x
P/S Ratio-4.5x
P/E RatioIs MRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNA income statement (TTM) | |
|---|---|
| Revenue | US$5.05b |
| Cost of Revenue | US$8.23b |
| Gross Profit | -US$3.18b |
| Other Expenses | US$2.69b |
| Earnings | -US$5.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.26 |
| Gross Margin | -62.99% |
| Net Profit Margin | -116.18% |
| Debt/Equity Ratio | 0% |
How did MRNA perform over the long term?
See historical performance and comparison